Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03989362 |
|
Recruitment Status :
Completed
First Posted : June 18, 2019
Last Update Posted : September 10, 2022
|
Sponsor:
Jounce Therapeutics, Inc.
Information provided by (Responsible Party):
Jounce Therapeutics, Inc.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of
submission even if the submission has not completed the
ClinicalTrials.gov Results Quality Control (QC) review process.
Results information is submitted to ClinicalTrials.gov by the sponsor or investigator,
and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff
do not verify the scientific validity or relevance of the submitted information.
All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | March 15, 2022 |
| Actual Study Completion Date : | March 15, 2022 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
April 11, 2023 | May 5, 2023 Submission with QC Comments |